These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24586244)

  • 41. Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis.
    Crescenzo F; Marastoni D; Zuco C; Pitteri M; Magliozzi R; Monaco S; Calabrese M
    Mult Scler Relat Disord; 2019 Jan; 27():305-311. PubMed ID: 30453199
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue.
    Kalkers NF; Vrenken H; Uitdehaag BM; Polman CH; Barkhof F
    Mult Scler; 2002 Oct; 8(5):410-4. PubMed ID: 12356208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brain macro- and microscopic damage in patients with paediatric MS.
    Absinta M; Rocca MA; Moiola L; Ghezzi A; Milani N; Veggiotti P; Comi G; Filippi M
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1357-62. PubMed ID: 20660915
    [TBL] [Abstract][Full Text] [Related]  

  • 44. T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients.
    Thaler C; Faizy T; Sedlacik J; Holst B; Stellmann JP; Young KL; Heesen C; Fiehler J; Siemonsen S
    PLoS One; 2015; 10(12):e0144693. PubMed ID: 26659852
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New rapid, accurate T
    Shepherd TM; Kirov II; Charlson E; Bruno M; Babb J; Sodickson DK; Ben-Eliezer N
    Neuroimage Clin; 2017; 14():363-370. PubMed ID: 28239545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of isolated lesions on white-matter fiber tracts in multiple sclerosis patients.
    Droby A; Fleischer V; Carnini M; Zimmermann H; Siffrin V; Gawehn J; Erb M; Hildebrandt A; Baier B; Zipp F
    Neuroimage Clin; 2015; 8():110-6. PubMed ID: 26106534
    [TBL] [Abstract][Full Text] [Related]  

  • 47. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G; Filippi M; Wolinsky JS
    Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis.
    De Stefano N; Bartolozzi ML; Nacmias B; Zipoli V; Mortilla M; Guidi L; Siracusa G; Sorbi S; Federico A; Amato MP
    Arch Neurol; 2004 Apr; 61(4):536-40. PubMed ID: 15096402
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis.
    Benedetti B; Rovaris M; Rocca MA; Caputo D; Zaffaroni M; Capra R; Bertolotto A; Martinelli V; Comi G; Filippi M
    Mult Scler; 2009 Jul; 15(7):789-94. PubMed ID: 19465450
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.
    Paolillo A; Pozzilli C; Giugni E; Tomassini V; Gasperini C; Fiorelli M; Mainero C; Horsfield M; Galgani S; Bastianello S; Buttinelli C
    Eur J Neurol; 2002 Nov; 9(6):645-55. PubMed ID: 12453081
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cortical Perfusion Alteration in Normal-Appearing Gray Matter Is Most Sensitive to Disease Progression in Relapsing-Remitting Multiple Sclerosis.
    Hojjat SP; Kincal M; Vitorino R; Cantrell CG; Feinstein A; Zhang L; Lee L; O'Connor P; Carroll TJ; Aviv RI
    AJNR Am J Neuroradiol; 2016 Aug; 37(8):1454-61. PubMed ID: 27012299
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relapsing-remitting multiple sclerosis: metabolic abnormality in nonenhancing lesions and normal-appearing white matter at MR imaging: initial experience.
    He J; Inglese M; Li BS; Babb JS; Grossman RI; Gonen O
    Radiology; 2005 Jan; 234(1):211-7. PubMed ID: 15528260
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions.
    Zurawski J; Tauhid S; Chu R; Khalid F; Healy BC; Weiner HL; Bakshi R
    Mult Scler; 2020 Feb; 26(2):177-187. PubMed ID: 31714181
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity.
    Regev K; Healy BC; Khalid F; Paul A; Chu R; Tauhid S; Tummala S; Diaz-Cruz C; Raheja R; Mazzola MA; von Glehn F; Kivisakk P; Dupuy SL; Kim G; Chitnis T; Weiner HL; Gandhi R; Bakshi R
    JAMA Neurol; 2017 Mar; 74(3):275-285. PubMed ID: 28114622
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Open trial of the effectiveness of interferon beta 1a (Avonex) in the treatment of multiple sclerosis in Poland: MRI results].
    Siger-Zajdel M; Lewańska M; Zaleski K; Członkowska A; Kwieciński H; Losy J; Podemski R; Stelmasiak Z; Selmaj K
    Neurol Neurochir Pol; 2003; 37(6):1185-97. PubMed ID: 15174232
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging.
    Rovaris M; Iannucci G; Falautano M; Possa F; Martinelli V; Comi G; Filippi M
    J Neurol Sci; 2002 Mar; 195(2):103-9. PubMed ID: 11897239
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study.
    Filippi M; Inglese M; Rovaris M; Sormani MP; Horsfield P; Iannucci PG; Colombo B; Comi G
    Neurology; 2000 Oct; 55(7):940-6. PubMed ID: 11061248
    [TBL] [Abstract][Full Text] [Related]  

  • 58. No regional gray matter atrophy differences between pediatric- and adult-onset relapsing-remitting multiple sclerosis.
    Donohue K; Cox JL; Dwyer MG; Aliotta R; Corwin M; Weinstock-Guttman B; Ann Yeh E; Zivadinov R
    J Neuroimaging; 2014; 24(1):63-7. PubMed ID: 23317029
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center data.
    Datta S; Staewen TD; Cofield SS; Cutter GR; Lublin FD; Wolinsky JS; Narayana PA; ;
    Mult Scler Relat Disord; 2015 Mar; 4(2):124-36. PubMed ID: 25787188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.
    Ge Y; Grossman RI; Udupa JK; Fulton J; Constantinescu CS; Gonzales-Scarano F; Babb JS; Mannon LJ; Kolson DL; Cohen JA
    Neurology; 2000 Feb; 54(4):813-7. PubMed ID: 10690968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.